Combination of Peptide YY3–36with GLP-17–36 amideCauses an Increase in First-Phase Insulin Secretion after IV Glucose
| Autor: | Ian F. Godsland, Ali Alsafi, Rachel C. Troke, Victoria Salem, Mandy Donaldson, Mohammad A. Ghatei, Kevin C.R. Baynes, James Minnion, Benjamin C. T. Field, Stephen R. Bloom, Tricia Tan, Akila De Silva, Shivani Misra |
|---|---|
| Přispěvatelé: | Medical Research Council (MRC) |
| Rok vydání: | 2014 |
| Předmět: |
Blood Glucose
Male FOOD-INTAKE Endocrinology Diabetes and Metabolism medicine.medical_treatment Clinical Biochemistry GASTRIC BYPASS Hot Topics in Translational Endocrinology Biochemistry 0302 clinical medicine Endocrinology APPETITE Glucagon-Like Peptide 1 Homeostasis Insulin Glucose homeostasis 0303 health sciences Glucose tolerance test medicine.diagnostic_test digestive oral and skin physiology Middle Aged Glucagon-like peptide-1 NEUROPEPTIDE-Y Female SENSITIVITY Life Sciences & Biomedicine hormones hormone substitutes and hormone antagonists Adult endocrine system medicine.medical_specialty 030209 endocrinology & metabolism Context (language use) Biology CELL FUNCTION Endocrinology & Metabolism Young Adult 03 medical and health sciences Insulin resistance Internal medicine Diabetes mellitus medicine Endocrine Research Humans Peptide YY Obesity BARIATRIC SURGERY 030304 developmental biology RELEASE Science & Technology PYY3-36 MORTALITY Biochemistry (medical) 1103 Clinical Sciences Glucose Tolerance Test Overweight medicine.disease Peptide Fragments Glucose 1114 Paediatrics and Reproductive Medicine Insulin Resistance |
| Zdroj: | E2324 E2317 The Journal of Clinical Endocrinology and Metabolism |
| ISSN: | 1945-7197 0021-972X |
| DOI: | 10.1210/jc.2014-2143 |
| Popis: | Context: The combination of peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) has been proposed as a potential treatment for diabetes and obesity. However, the combined effects of these hormones, PYY3–36 and GLP-17–36 amide, on glucose homeostasis are unknown. Objective: This study sought to investigate the acute effects of PYY3–36 and GLP-17–36 amide, individually and in combination, on insulin secretion and sensitivity. Setting and Design: Using a frequently sampled iv glucose tolerance test (FSIVGTT) and minimal modeling, this study measured the effects of PYY3–36 alone, GLP-17–36 amide alone, and a combination of PYY3–36 and GLP-17–36 amide on acute insulin response to glucose (AIRg) and insulin sensitivity index (SI) in 14 overweight human volunteers, studied in a clinical research facility. Results: PYY3–36 alone caused a small but nonsignificant increase in AIRg. GLP-17–36 amide alone and the combination of PYY3–36 and GLP-17–36 amide did increase AIRg significantly. No significant differences in SI were observed with any intervention. Conclusions: PYY3–36 lacks any significant acute effects on first-phase insulin secretion or SI when tested using an FSIVGTT. Both GLP-17–36 amide alone and the combination of PYY3–36 and GLP-17–36 amide increase first-phase insulin secretion. There does not seem to be any additive or synergistic effect between PYY3–36 and GLP-17–36 amide on first-phase insulin secretion. Neither hormone alone nor the combination had any significant effects on SI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|